Pegzilarginase-nbln

Para qué se usa Pegzilarginase-nbln

Cita de la sección «Indications and Usage» (indicaciones y uso) de la etiqueta aprobada por la FDA. Se muestra en inglés, tal como la publica la FDA.

LOARGYS is indicated for the treatment of hyperargininemia in adult and pediatric patients 2 years of age and older with Arginase 1 Deficiency (ARG1-D), in conjunction with dietary protein restriction. This indication is approved under accelerated approval based on reduction of plasma arginine […]. …

— Etiqueta de la FDA: Loargys, Immedica Pharma US Inc., vigente desde el 23 de febrero de 2026. Leer la etiqueta completa en DailyMed →

Etiqueta citada: la de la presentación más común (injection, intravenous), Loargys, Immedica Pharma US Inc.; abarca 2 productos del directorio NDC de la FDA. Las citas sobre efectos secundarios, interacciones, dosis y embarazo de abajo vienen de esta misma etiqueta.

Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.

Advertencia en recuadro

La advertencia en recuadro («caja negra») es la advertencia más seria de la FDA en la etiqueta de un medicamento, para riesgos graves o mortales.

Esta etiqueta tiene una advertencia en recuadro. Su título: WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS. Leerla en la etiqueta completa →

Pegzilarginase-nbln: lo que dice la advertencia en recuadro

Cita de la advertencia en recuadro (Boxed Warning) de la etiqueta aprobada por la FDA. Se muestra en inglés.

WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. Initiate LOARGYS in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment.

Leer más de esta sección

If a severe hypersensitivity reaction (e.g. anaphylaxis) occurs, discontinue LOARGYS and immediately initiate appropriate medical treatment, including use of epinephrine. Inform patients of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis and to seek immediate medical care should symptoms occur [see Warnings and Precautions (5.1)]. WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS See full prescribing information for complete boxed warning. Initiate LOARGYS in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. (5.1) If a severe hypersensitivity reaction (e.g. anaphylaxis) occurs, discontinue LOARGYS, and immediately initiate appropriate medical treatment, including use of epinephrine. (5.1)

— Etiqueta de la FDA: Loargys, Immedica Pharma US Inc., vigente desde el 23 de febrero de 2026. Leer la etiqueta completa en DailyMed →

Efectos secundarios de Pegzilarginase-nbln

Cita de la sección «Adverse Reactions» (reacciones adversas) de la etiqueta aprobada por la FDA. Se muestra en inglés. Avise a su médico de cualquier efecto secundario que le preocupe.

The following adverse reactions are described below and elsewhere in the labeling:

• Hypersensitivity Reactions [see Warnings and Precautions (5.1)]. Most common adverse reactions (>10%) are vomiting, pyrexia, infusion associated reactions and constipation.

Leer más de esta sección

(6.1) To report SUSPECTED ADVERSE REACTIONS, contact Immedica at toll-free phone 1-844-627-4687 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of LOARGYS was evaluated in a randomized, double-blind, placebo-controlled trial in pediatric and adult patients with ARG1-D (Trial 1). Additional safety information was derived from Trial 2, a Phase 1 open-label trial that evaluated 16 patients between the ages of 5 to 31 years to assess safety, PK and PD of LOARGYS, and Trial 3, an open-label extension including 14 patients from Trial 2. Adverse Reactions from Trial 1 (Double-Blind Period) A total of 21 patients between the ages of 2 and 28 years of age, at enrollment, received intravenous LOARGYS dosages up to 0.2 mg/kg once weekly and 11 patients received placebo for 24 weeks [see Clinical Studies (14)]. Table 1 summarizes the adverse reactions reported in ≥ 2 LOARGYS-treated patients and at a higher incidence in LOARGYS-treated patients compared to placebo-treated patients in Trial 1. Table 1: Common Adverse Reactions a in Pediatric and Adult Patients with ARG1-D in Trial 1 a Common adverse reactions were those that occurred in ≥ 2 LOARGYS-treated patients and at a higher incidence in LOARGYS-treated patients compared to placebo-treated patients. b Infusion-associated reactions are defined as reactions occurring within 4 hours after the infusion and included pruritus, arm swelling, and abdominal pain in LOARGYS-treated patients. c Includes reactions that were classified as hypersensitivity during the trial and reactions that were assessed as hypersensitivity based on symptoms and temporal relationship with drug. Adverse Reaction LOARGYS N = 21 n (%) Placebo N = 11 n (%) Vomiting 7 (33) 3 (27) Pyrexia 4 (19) 1 (9) Infusion Associated Reaction b 3 (14) 1 (9) Constipation 3 (14) 1 (9) Dizziness 2 (10) 0 Fall 2 (10) 0 Hypersensitivity c 2 (10) 0 Nasopharyngitis 2 (10) 0 Rhinorrhoea 2 (10) 0 Alanine aminotransferase increased 2 (10) 0 Aspartate aminotransferase increased 2 (10) 0 Description of Selected Adverse Reactions Hypersensitivity Reactions: Hypersensitivity reactions with symptoms including facial swelling, rash, flushing and dyspnea were reported in 13% (6/48) of LOARGYS-treated patients during clinical trials [see Warnings and Precautions (5.1)]. Injection Site Reactions: Injection site reactions were reported in 14% (6/44) of patients after subcutaneous LOARGYS administration during the open-label extension periods in Trial 1 and Trial 3.

— Etiqueta de la FDA: Loargys, Immedica Pharma US Inc., vigente desde el 23 de febrero de 2026. Esto es solo una parte de la sección. Leer la etiqueta completa en DailyMed →

Dosis de Pegzilarginase-nbln

Cita de la sección «Dosage and Administration» (dosis y administración) de la etiqueta aprobada por la FDA. Se muestra en inglés. Su dosis es la que le receta su médico: no la cambie por su cuenta.

• Administer LOARGYS under the supervision of a health care provider knowledgeable in the management of hypersensitivity reactions including anaphylaxis. (2.1)
• Initiate LOARGYS in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. (2.1)
• Consider pre‑medication with antihistamines. (2.1)
• Obtain a baseline plasma arginine concentration prior to initiating treatment.

Leer más de esta sección

(2.1)

• Recommended starting dosage of LOARGYS is 0.1 mg/kg administered by intravenous infusion once weekly. (2.2)
• Maximum recommended dosage is 0.2 mg/kg once weekly. (2.2)
• See the Full Prescribing Information for recommended titration and maintenance dosage and recommended plasma arginine level testing during treatment. (2.2)
• After eight weeks of once weekly intravenous LOARGYS, patients may be switched to once weekly subcutaneous LOARGYS at the same dosage of intravenous therapy. (2.4)
• See Full Prescribing Information for dosage and administration modifications due to hypersensitivity reactions. (2.5)
• See Full Prescribing Information for instructions on preparation, storage, and administration. (2.7, 2.8, 2.9, 2.10) 2.1 Recommendations Prior to LOARGYS Treatment
• Administer LOARGYS under the supervision of a healthcare provider knowledgeable in the management of hypersensitivity reactions including anaphylaxis [see Warnings and Precautions (5.1)].
• Initiate LOARGYS in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment [see Warnings and Precautions (5.1)].
• Obtain a baseline plasma arginine concentration.
• Consider pre-medication with antihistamines [see Warnings and Precautions (5.1)]. 2.2 Recommended Dosage and Administration The recommended starting dosage of LOARGYS is 0.1 mg/kg administered via intravenous infusion once weekly [see Dosage and Administration (2.9)]. For the recommended dosage use actual body weight. Recommended Adjustment, Maximum Dosage, and Monitoring To maximize the time within the normal range of 40 to 115 micromolar, dose adjustments should be aimed at achieving a pre-dose level of plasma arginine near the upper limit of normal (ULN). After four weeks of LOARGYS administration, measure pre-dose plasma arginine (168 hours after prior dose) to determine the need for dosage adjustment. If two consecutive weekly pre-dose plasma arginine measurements are not in the desired therapeutic range, increase or decrease the weekly LOARGYS dosage as follows:
• Below 50 micromolar, reduce the weekly LOARGYS dosage by 0.05 mg/kg.
• Above 150 micromolar, increase the weekly LOARGYS dosage by 0.05 mg/kg. The maximum recommended LOARGYS dosage is 0.2 mg/kg once weekly. Monitor plasma arginine levels (prior to LOARGYS dosing) weekly for 2 weeks after any LOARGYS dosage adjustment and as clinically indicated.

— Etiqueta de la FDA: Loargys, Immedica Pharma US Inc., vigente desde el 23 de febrero de 2026. Esto es solo una parte de la sección. Leer la etiqueta completa en DailyMed →

Pegzilarginase-nbln en el embarazo

Cita de la parte sobre embarazo (Pregnancy) de la etiqueta aprobada por la FDA. Se muestra en inglés. Pregunte a su médico antes de tomar cualquier medicamento si está embarazada o planea estarlo.

Risk Summary There are no available data on LOARGYS use in pregnant females to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. In animal reproduction studies, intravenous administration of pegzilarginase-nbln to pregnant rats and rabbits during organogenesis resulted in maternal toxicity with associated increased incidence of fetal growth deficiencies (see Data).

Leer más de esta sección

The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data In an embryofetal development study in pregnant rats with normal circulating arginine levels, intravenous pegzilarginase-nbln was administered throughout organogenesis at 0.1, 0.3, and 1 mg/kg/dose on gestation days 6, 11, and 16. Maternal toxicity was observed as reduced body weight, reduced body weight gain, reduced food consumption and reduced mean gravid uterine weights at 1 mg/kg/dose (8-fold the human exposure, based on AUC at the maximum recommended human dose (MRHD), with associated decreases in fetal body weights and increased fetal developmental malformations and variations at this dose. In an embryofetal development study in pregnant rabbits with normal circulating arginine levels, intravenous pegzilarginase-nbln was administered throughout organogenesis at 0.06, 0.1, and 0.3 mg/kg/dose on gestation days 6, 13, and 20. Maternal toxicity was observed as decreased maternal body weights, food consumption and mean gravid uterine weights at 0.3 mg/kg/dose (3-fold the human exposure, based on AUC at the MRHD), with associated decreases in fetal body weights and increased developmental malformations and variations at this dose. In a pre- and postnatal development study in pregnant rats with normal circulating arginine levels, intravenous pegzilarginase-nbln was administered at 0.1, 0.3 and 1 mg/kg/dose once weekly from gestation day 6 to lactation day 20. Maternal toxicity included reduced body weight and food consumption during gestation and lactation with associated reduced pup body weight at 1 mg/kg/dose (8-fold the human exposure based on AUC at the MRHD). Male pups exposed to 1 mg/kg/dose through gestation and lactation also had impaired learning and memory in the passive avoidance test.

— Etiqueta de la FDA: Loargys, Immedica Pharma US Inc., vigente desde el 23 de febrero de 2026. Leer la etiqueta completa en DailyMed →

Presentaciones y vía de administración

Empresas que tienen este medicamento

Empresas en el directorio NDC de la FDA: la empresa que aparece en el envase (fabricante o distribuidor), con su número de productos con receta.

• Immedica Pharma US Inc.2 productos

Historial de aprobación de la FDA

• BLA: Solicitud de licencia de productos biológicos (BLA): así se aprueba un medicamento biológico (hecho a partir de células vivas).

Escasez

La lista de escasez de la FDA no incluye estos productos.

Base de datos de escasez de medicamentos de la FDA →

Retiros del mercado

No aparece ningún retiro vinculado a estos productos (por su código NDC) en los informes de la FDA.

Identificadores oficiales

Siguientes pasos

• Encuentre una farmacia cerca de ustedPregunte qué precio le corresponde y si su producto está afectado por un retiro
• Últimos retiros de medicamentos de la FDATodos los medicamentos, los más recientes primero
• Immedica Pharma US Inc.Fabricante o distribuidor
• Todos los medicamentos con receta de la A a la ZBusque por nombre genérico, de marca o en español

Fuentes

1. Etiqueta aprobada por la FDA en DailyMed (Biblioteca Nacional de Medicina) — Loargys, Immedica Pharma US Inc., vigente desde el 23 de febrero de 2026; vía openFDA, datos de la FDA exportados el 30 de octubre de 2026, consultados el 31 de octubre de 2026
2. NDC Directory (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 30 de octubre de 2026, consultados el 31 de octubre de 2026
3. Drugs@FDA (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 30 de octubre de 2026, consultados el 31 de octubre de 2026
4. Drug recall enforcement reports (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 27 de octubre de 2026, consultados el 31 de octubre de 2026
5. Drug shortages (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 30 de octubre de 2026, consultados el 31 de octubre de 2026

La FDA ofrece los datos de openFDA tal cual; pueden estar incompletos. Guíese siempre por la etiqueta que viene con su medicamento. Buscador de informes de retiros de la FDA →

Informar un error → · Información para fabricantes de medicamentos